Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study.
Trněný M, Avigdor A, McKinney MS, Paneesha S, Wahlin BE, Hrom JS, Cunningham D, Morley N, Canales M, Bastos-Oreiro M, Belada D, Devizzi L, Zheng F, DeMarini DJ, Jiang W, Jiang P, Lynch RC. Trněný M, et al. EClinicalMedicine. 2023 Aug 18;63:102130. doi: 10.1016/j.eclinm.2023.102130. eCollection 2023 Sep. EClinicalMedicine. 2023. PMID: 37662520 Free PMC article.
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.
Katz DA, Morris JD, Chu MP, David KA, Thieblemont C, Morley NJ, Khan SS, Viardot A, Martín García-Sancho A, Rodríguez-García G, Bastos-Oreiro M, Lee ST, Kormany W, Chen Y, Wong HL, Anderson AA, Katlinskaya Y, Avilion AA, Dai T, González-Barca E. Katz DA, et al. Leuk Lymphoma. 2022 Sep;63(9):2063-2073. doi: 10.1080/10428194.2022.2064981. Epub 2022 May 3. Leuk Lymphoma. 2022. PMID: 35503708 Free article. Clinical Trial.
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Abrisqueta P, González-Barca E, Panizo C, Pérez JMA, Miall F, Bastos-Oreiro M, Triguero A, Banerjee L, McMillan A, Seymour E, Hirata J, de Guzman J, Sharma S, Jin HY, Musick L, Diefenbach C. Abrisqueta P, et al. Among authors: bastos oreiro m. Lancet Haematol. 2024 Feb;11(2):e136-e146. doi: 10.1016/S2352-3026(23)00345-9. Epub 2024 Jan 5. Lancet Haematol. 2024. PMID: 38190832 Clinical Trial.
Thalidomide as treatment of refractory thoracic Rosai-Dorfman disease.
Hoyo-Muñoz A, Collado-Borrell R, Escudero-Vilaplana V, Bastos-Oreiro M, Herranz-Alonso A, Sanjurjo-Sáez M. Hoyo-Muñoz A, et al. J Clin Pharm Ther. 2022 Apr;47(4):548-551. doi: 10.1111/jcpt.13513. Epub 2021 Sep 12. J Clin Pharm Ther. 2022. PMID: 34514634
Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin's lymphoma.
Bastos-Oreiro M, Suárez-González J, Andrés-Zayas C, Carrión NC, Moreno S, Carbonell D, Chicano M, Muñiz P, Sanz L, Diaz-Crespo FJ, Menarguez J, Diez-Martín JL, Buño I, Martínez-Laperche C. Bastos-Oreiro M, et al. Sci Rep. 2021 Nov 24;11(1):22815. doi: 10.1038/s41598-021-02362-4. Sci Rep. 2021. PMID: 34819573 Free PMC article.
Allogeneic CD34-selected stem cell boost as salvage treatment of life-threatening infection and severe cytopenias after CAR-T cell therapy.
de Tena PS, Bailén R, Oarbeascoa G, Gómez-Centurión I, Pérez-Corral A, Carbonell D, Martínez-Laperche C, Sancho M, Bastos-Oreiro M, Conde-Royo D, Fernández-Caldas P, Muñoz C, Sabell S, Buño I, Anguita J, Díez-Martín JL, Kwon M. de Tena PS, et al. Transfusion. 2022 Oct;62(10):2143-2147. doi: 10.1111/trf.17071. Epub 2022 Aug 20. Transfusion. 2022. PMID: 35986653
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
Mussetti A, Bento L, Bastos-Oreiro M, Rius-Sansalvador B, Albo C, Bailen R, Barba P, Benzaquén A, Briones J, Caballero AC, Campos A, Español I, Ferra C, López SG, González Sierra PA, Guerra LM, Hernani R, Iacoboni G, Jiménez-Ubieto A, Kwon M, Corral LL, López-Godino O, Munoz MCM, Martínez-Cibrián N, Gómez JM, Pérez-Ortega L, Ortí G, Ortiz-Maldonado V, Pascual MJ, Perera M, Perez A, Reguera JL, Sanchez JM, Sanz J, Torrent A, Yáñez L, Varela R, Echechipia IC, Caballero D, Sureda A. Mussetti A, et al. Bone Marrow Transplant. 2023 Jun;58(6):673-679. doi: 10.1038/s41409-023-01949-x. Epub 2023 Mar 14. Bone Marrow Transplant. 2023. PMID: 36918682
Comparing R-Bendamustine vs. R-CHOP Plus Maintenance Therapy as First-Line Systemic Treatment in Follicular Lymphoma: A Multicenter Retrospective GELTAMO Study.
Bastos-Oreiro M, Gutierrez A, Cabero A, López J, Villafuerte P, Jiménez-Ubieto A, de Oña R, De la Fuente A, Navarro B, Peñalver J, Martínez P, Alonso C, Infante M, Córdoba R, Perez-Montero B, Pérez de Oteyza J, González de Villambrosio S, Fernández-Caldas P, Del Campo R, García Belmonte D, Diaz-Gálvez J, Salar A, Sancho JM. Bastos-Oreiro M, et al. Cancers (Basel). 2024 Mar 26;16(7):1285. doi: 10.3390/cancers16071285. Cancers (Basel). 2024. PMID: 38610963 Free PMC article.
Aprepitant in refractory pruritus of systemic lymphoproliferative disorders.
Pulido-Perez A, Carretero-Lopez F, Bergon-Sendin M, Nieto-Benito LM, Romero-Jimenez R, Dorado-Herrero N, Bastos-Oreiro MB, Suárez-Fernández R. Pulido-Perez A, et al. J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e422-e424. doi: 10.1111/jdv.16370. Epub 2020 Apr 30. J Eur Acad Dermatol Venereol. 2020. PMID: 32180276 No abstract available.
60 results